- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Co-Diagnostics Enters Into Lease for New Laboratory Facility
Co-Diagnostics announced the leasing of a new CGMP-ready and Biological Safety Level 2 laboratory facility in Salt Lake City.
Co-Diagnostics (NASDAQ:CODX) announced the leasing of a new CGMP-ready and Biological Safety Level 2 laboratory facility in Salt Lake City, Utah.
As quoted in the press release:
Co-Diagnostics CEO Dwight Egan remarked, “The upgraded facility is nearly perfectly appointed with the necessary amenities to immediately commence production operations. This site will help us to reduce our dependence on outside locations to complete robust validations of the Company’s products, and represents the next step in our growth as a world-class developer of molecular diagnostics. Our trained personnel will now have the capacity to manufacture high-quality products that meet the standards of the U.S. Food and Drug Administration, preparing the Company to seek future FDA approvals for sale domestically and export abroad.”
Mr. Egan continued, “This is another important milestone in the development of Co-Diagnostics as an emerging leader in the molecular diagnostics industry. We are bringing disruptive technology to the market that will dramatically improve test accuracy by reducing false positives via our CoPrimers™ technology, and facilitate multiplexing to test for a broad range of disease states in a patient in a single test which will cut costs to healthcare systems. We are excited with the opportunities ahead in the coming years.”
Click here to read the full press release.
Source: www.businesswire.com
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.